Centre for Infectious Diseases and Epidemiology, Central Institute of the Valais Hospitals Sion, Switzerland.
Front Endocrinol (Lausanne). 2012 Jan 12;2:116. doi: 10.3389/fendo.2011.00116. eCollection 2011.
Combined prolactin (PRL) and growth hormone (GH) secretion by a single pituitary tumor can occur in approximately 5% of cases. However, in all previously reported patients, combined secretion of both hormones was present at the time of diagnosis. Here we describe a patient initially diagnosed with a pure prolactin-secreting microadenoma, who experienced the progressive apparition of symptomatic autonomous GH secretion while on intermittent long term dopamine agonist therapy. She was operated on, and immunohistochemical analysis of tumor tissue confirmed the diagnosis of pituitary adenoma with uniform co-staining of all cells for both GH and PRL. This patient represents the first documented occurrence of asynchronous development of combined GH and PRL secretion in a pituitary adenoma. Although pathogenic mechanisms implicated remain largely speculative, it emphasizes the need for long term hormonal follow up of patients harboring prolactinomas.
单一垂体瘤同时分泌泌乳素(PRL)和生长激素(GH)的情况约占所有病例的 5%。然而,所有既往报道的此类患者均在确诊时就已同时分泌这两种激素。我们在此描述了一位最初诊断为单纯泌乳素分泌型微腺瘤的患者,她在间歇性长期多巴胺激动剂治疗过程中逐渐出现有症状的自主 GH 分泌。我们对其进行了手术,肿瘤组织的免疫组织化学分析证实了垂体腺瘤的诊断,所有细胞均同时均匀染色 GH 和 PRL。该患者是首例记录到垂体腺瘤中 GH 和 PRL 分泌异步发展的病例。虽然目前涉及的发病机制仍在推测中,但它强调了需要对存在泌乳素瘤的患者进行长期的激素随访。